Skip to main content

Adjuvant Capital Adds Philippe Dro As Partner

Life sciences investment firm Adjuvant Capital has hired Phillipe Dro, Pharm. D., MBA, as a partner. Dro will be based in Zurich, Switzerland, and is a biopharma and medical device entrepreneur and executive with more than 25 years of experience.

"We are excited to welcome someone of Philippe's caliber to the Adjuvant team," said Glenn Rockman, managing partner at Adjuvant Capital. "With decades of leadership in the life science and medical device industries as a CEO, founder and investor, Philippe will play an important role in expanding Adjuvant's presence and investment activities across Europe."

Most recently, Dro served as a board member and chief business officer of Themis, an Austrian vaccine development-focused biotech company, until its acquisition by Merck & Co. (known as MSD outside of the United States). He also served as CEO and member of the Supervisory Board of Swiss-based GlycoVaxyn AG, leading it through its acquisition by GSK in 2015. Earlier in his career, Dro was chairman and CEO of Endoart S.A., a medtech company, where he led a corporate turnaround that resulted in its acquisition by Allergan. He was part of the founding team of a G-Protein Coupled Receptor (GPCR) biotech company, Axovan, which was acquired by Actelion in 2003. Dro previously worked in the pharmaceutical industry, where he held various operational and managerial positions at Novartis, SkyePharma and Antares Pharma.

"Adjuvant takes a truly unique and disruptive position in supporting companies and technologies addressing important global health challenges with the discipline and focus of a venture capital fund," Dro added. "I believe that the potential impact of such an approach can be tremendous for society, as well as for investors. I am very excited to work with the Adjuvant team and I share their vision of growing companies that will directly benefit underserved populations."


© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.